82 related articles for article (PubMed ID: 30591504)
1. Metabolomics-based Discovery of Serum Biomarkers to Predict the Side-effects of Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma.
Nishiumi S; Fujigaki S; Kobayashi T; Kojima T; Ito Y; Daiko H; Kato K; Shoji H; Kodama Y; Honda K; Yoshida M
Anticancer Res; 2019 Jan; 39(1):519-526. PubMed ID: 30591504
[TBL] [Abstract][Full Text] [Related]
2. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach.
Fujigaki S; Nishiumi S; Kobayashi T; Suzuki M; Iemoto T; Kojima T; Ito Y; Daiko H; Kato K; Shouji H; Honda K; Azuma T; Yoshida M
Biomark Med; 2018 Aug; 12(8):827-840. PubMed ID: 30043633
[TBL] [Abstract][Full Text] [Related]
3. Alteration of plasma metabolites associated with chemoradiosensitivity in esophageal squamous cell carcinoma via untargeted metabolomics approach.
Zhang Y; Wang J; Dai N; Han P; Li J; Zhao J; Yuan W; Zhou J; Zhou F
BMC Cancer; 2020 Sep; 20(1):835. PubMed ID: 32878621
[TBL] [Abstract][Full Text] [Related]
4. Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers.
Wu Y; Chen J; Zhao L; Li Q; Zhu J; Yang H; Guo S; Xi M
Cancer Res Treat; 2021 Jan; 53(1):172-183. PubMed ID: 32898941
[TBL] [Abstract][Full Text] [Related]
5. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers.
Xu J; Chen Y; Zhang R; Song Y; Cao J; Bi N; Wang J; He J; Bai J; Dong L; Wang L; Zhan Q; Abliz Z
Mol Cell Proteomics; 2013 May; 12(5):1306-18. PubMed ID: 23397110
[TBL] [Abstract][Full Text] [Related]
6. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
[TBL] [Abstract][Full Text] [Related]
7. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinoma.
Suzuki T; Yajima S; Ishioka N; Nanami T; Oshima Y; Washizawa N; Funahashi K; Otsuka S; Nemoto T; Shimada H
Esophagus; 2018 Oct; 15(4):294-300. PubMed ID: 29959634
[TBL] [Abstract][Full Text] [Related]
9. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Localized Esophageal Squamous Cell Carcinoma Patients Treated With Definitive Concurrent Chemoradiotherapy Using Either Standard or High Radiotherapy Dose: A Retrospective Study Controlling for Organ at Risk Dose.
Li CC; Fang HY; Lin CY; Shen WC; Chien CR
Anticancer Res; 2019 Jan; 39(1):511-517. PubMed ID: 30591503
[TBL] [Abstract][Full Text] [Related]
11. Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Liu SL; Xi M; Yang H; Yang YD; Wu YJ; Zhao L; Zhang P; Luo LL; Liu MZ
Ann Surg Oncol; 2016 Jan; 23(1):273-81. PubMed ID: 26215200
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy for esophageal carcinoma.
Zhang X; Watson DI; Jamieson GG; Bessell JR; Devitt PG
Dis Esophagus; 2005; 18(2):104-8. PubMed ID: 16053485
[TBL] [Abstract][Full Text] [Related]
13. An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma.
Zhang C; Zhang G; Sun N; Zhang Z; Xue L; Zhang Z; Yang H; Luo Y; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Wang L; Che Y; Wang F; Wang S; Gao S; Xue Q; Zhang Y; He J
Signal Transduct Target Ther; 2020 Sep; 5(1):182. PubMed ID: 32883946
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
[TBL] [Abstract][Full Text] [Related]
15. DNA repair biomarkers predict response to neoadjuvant chemoradiotherapy in esophageal cancer.
Alexander BM; Wang XZ; Niemierko A; Weaver DT; Mak RH; Roof KS; Fidias P; Wain J; Choi NC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):164-71. PubMed ID: 22000749
[TBL] [Abstract][Full Text] [Related]
16. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.
Taylor Ripley R; Surman DR; Diggs LP; Trepel JB; Lee MJ; Ryan J; Davis JL; Steinberg SM; Hernandez JM; Hoang C; Kenney CM; Bond CD; Kunst TF; Letai A; Schrump DS
BMC Gastroenterol; 2018 Jun; 18(1):94. PubMed ID: 29933761
[TBL] [Abstract][Full Text] [Related]
17. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
[TBL] [Abstract][Full Text] [Related]
18. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
20. Increasing toxicity during neoadjuvant radiochemotherapy as positive prognostic factor for patients with esophageal carcinoma.
Hennies S; Hermann RM; Gaedcke J; Grade M; Hess CF; Christiansen H; Wolff HA
Dis Esophagus; 2014; 27(2):146-51. PubMed ID: 23574528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
